×

Endologix to Participate in Four Investor Conferences in November

IRVINE, Calif., Nov. 9, 2015 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today that John McDermott, Chief Executive Officer, Vaseem Mahboob, Chief Financial Officer, and Bob Mitchell, President, are scheduled to participate at four investor conferences in November. The first conference is the Stephens Fall Investment Conference in New York City.

Event: Stephens Fall Investment Conference
Date: Tuesday, November 10, 2015
Time: 9:00 am ET
Participant: Bob Mitchell, President

The second conference is the Credit Suisse 24th Annual Healthcare Conference in Scottsdale, AZ.

Event: Credit Suisse 24th Annual Healthcare Conference
Date: Tuesday, November 10, 2015
Time: 4:30 pm ET / 2:30 pm MT
Participant: John McDermott, Chief Executive Officer

The third conference is the Stifel 2015 Healthcare Conference in New York City.

Event: Stifel 2015 Healthcare Conference
Date: Tuesday, November 17, 2015
Time: 8:45 am ET
Participants: John McDermott, Chief Executive Officer, and Vaseem Mahboob, Chief Financial Officer

The fourth conference is the Canaccord Medical Technologies and Diagnostics Forum in New York City.

Event: Canaccord Medical Technology and Diagnostics Forum
Date: Thursday, November 19, 2015
Time: 8:00 am ET
Participants: John McDermott, Chief Executive Officer, and Vaseem Mahboob, Chief Financial Officer

An audio webcast of the Company's presentations at these conferences will be available by visiting the investor relations section of Endologix's website at www.endologix.com. A replay of the presentation will be available for 30 days.

About Endologix, Inc.

Endologix, Inc. develops and manufactures minimally invasive treatments for aortic disorders. The Company's focus is endovascular stent grafts for the treatment of abdominal aortic aneurysms (AAA). AAA is a weakening of the wall of the aorta, the largest artery in the body, resulting in a balloon-like enlargement. Once AAA develops, it continues to enlarge and, if left untreated, becomes increasingly susceptible to rupture. The overall patient mortality rate for ruptured AAA is approximately 80%, making it a leading cause of death in the U.S.

CONTACT: COMPANY CONTACT: Endologix, Inc. John McDermott, CEO Vaseem Mahboob, CFO (949) 595-7200 www.endologix.com INVESTOR CONTACTS: The Ruth Group Nick Laudico (646) 536-7030 Zack Kubow (646) 536-7020Source:Endologix